Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276209 · ClinicalTrials.gov registry record · Phase 3
Dasotraline Adult ADHD Study
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 636
- Enrollment target
NCT02276209 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 636 participants.
The verdict
NCT02276209, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 636 participants
- Enrollment target
Study Summary
This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD.
Interventions
- OTHER Placebo
- DRUG Dasotraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 636 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02276209
The ClinicalTrials.gov registry entry for NCT02276209 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 636 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02276209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02276209 about?
NCT02276209 is a clinical study titled "Dasotraline Adult ADHD Study". This is a randomized, double blind, multicenter, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in adults with ADHD.
What is the current status of trial NCT02276209?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 636 participants. The study started on 2014-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02276209?
The interventions under investigation include: Placebo (OTHER), Dasotraline (DRUG).
Who is sponsoring clinical trial NCT02276209?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.